Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
SAN DIEGO, June 29, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that it will present an analysis of phase 2 clinical data on SM04690 for the treatment of knee osteoarthritis (OA) as a...
-
Phase 2 data in osteoarthritis and preclinical data in tendinopathy and psoriasis demonstrated the emerging breadth of the Samumed pipeline in arthritis related diseases and in dermatology SAN DIEGO,...
-
SAN DIEGO, June 08, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that it will present clinical and preclinical data on two of the company’s investigational drugs, SM04690, for the...
-
SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, a leader in Wnt signaling pathway research and development, today announced that it will present clinical and pre-clinical data on its small...
-
SAN DIEGO, May 11, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, a leader in Wnt signaling pathway research and development, today announced it will present preclinical data on the company’s...
-
SAN DIEGO, May 07, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, a leader in Wnt research and development, presented its most recent clinical and preclinical data for two of the company’s investigational...
-
SAN DIEGO, April 23, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, a leader in Wnt research and development, today announced it will present its most recent clinical and preclinical data on the company’s...
-
SAN DIEGO, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Samumed, LLC, today announced the dosing of the first degenerative disc disease (DDD) patient in its Phase 1 trial of SM04690, a small molecule Wnt...
-
SAN DIEGO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Samumed, LLC, today announced the dosing of the first cancer patient in its Phase 1 trial of SM08502, a small molecule Wnt pathway inhibitor in oral...
-
- Data support potential of SM04690 as a disease modifying drug for knee osteoarthritis - SAN DIEGO, Nov. 06, 2017 (GLOBE NEWSWIRE) -- Samumed, LLC, today announced detailed results from the Phase...